Pub Date : 2024-10-14DOI: 10.1097/ju.0000000000004293
Shellie D Ellis,Ted A Skolarus
{"title":"Furthering the capacity of urologists to shape the field of dissemination and implementation science and enhance clinical practice.","authors":"Shellie D Ellis,Ted A Skolarus","doi":"10.1097/ju.0000000000004293","DOIUrl":"https://doi.org/10.1097/ju.0000000000004293","url":null,"abstract":"","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"56 1","pages":"101097JU0000000000004293"},"PeriodicalIF":0.0,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-20DOI: 10.1097/ju.0000000000004242
Jonathan S Ellison,Kathryn E Flynn,Katherine Sheridan,Samantha Siodlarz,Jodi Antonelli,Christopher E Bayne,Hunter Beck,Christina Ching,Pankaj P Dangle,Casey Dauw,Carley Davis,Kim Hollander,Dirk Lange,Kristi Ouimet,Carswell Ouimet,Amy Y Pan,Kristina Penniston,Charles D Scales,Nayan Shah,Ryan Spiardi,Necole Streeper,Kristin Whitmore,Mike Witt,Liyun Zhang,Gregory E Tasian
PURPOSETo ensure that research on kidney stones provides meaningful impact for the kidney stone community, patients and caregivers should be engaged as stakeholders in clinical trial design, starting at study inception. This project aimed to elicit, refine, and prioritize research ideas from kidney stone stakeholders to develop a patient-centered research agenda for clinical trials.MATERIALS AND METHODSThe Kidney Stone Engagement Core, a group of patients, caregivers, advocates, clinicians, and researchers, executed an iterative process of surveys and focus groups to elicit and refine research themes, which were then translated into research questions. A separate group of patients, caregivers, and clinicians prioritized these questions through parallel modified Delphi and crowd-sourced digital platforms. A research agenda was developed by the Kidney Stone Engagement Core based on the highest rated questions during a hybrid virtual/in-person capstone session.RESULTSA total of 70 individuals (57 patients and caregivers, 13 researchers and clinicians) participated in the elicitation, 20 individuals (15 patients and caregivers, 5 researchers and clinicians) participated in refinement, and an additional 80 individuals (81 patients and caregivers, 9 researchers and clinicians) participated in prioritization. Key novel themes emerged from elicitation and refinement: ureteral stents, genetic evaluation, shared surgical decision-making, key subgroups, cumulative disease burden, genetic evaluation, and psychosocial support. Stakeholders generated 6 proposed trials from these themes focused on surveillance, surgical intervention, and medical prevention.CONCLUSIONSPatients and caregivers valued comparative effectiveness kidney stone research that focused on individualized care, shared decision-making, and improvement of patient-reported experiences. This process provided actionable recommendations for future patient-centered clinical trials within kidney stone disease.
{"title":"A Patient-Prioritized Research Agenda for Clinical Trials in Kidney Stone Disease.","authors":"Jonathan S Ellison,Kathryn E Flynn,Katherine Sheridan,Samantha Siodlarz,Jodi Antonelli,Christopher E Bayne,Hunter Beck,Christina Ching,Pankaj P Dangle,Casey Dauw,Carley Davis,Kim Hollander,Dirk Lange,Kristi Ouimet,Carswell Ouimet,Amy Y Pan,Kristina Penniston,Charles D Scales,Nayan Shah,Ryan Spiardi,Necole Streeper,Kristin Whitmore,Mike Witt,Liyun Zhang,Gregory E Tasian","doi":"10.1097/ju.0000000000004242","DOIUrl":"https://doi.org/10.1097/ju.0000000000004242","url":null,"abstract":"PURPOSETo ensure that research on kidney stones provides meaningful impact for the kidney stone community, patients and caregivers should be engaged as stakeholders in clinical trial design, starting at study inception. This project aimed to elicit, refine, and prioritize research ideas from kidney stone stakeholders to develop a patient-centered research agenda for clinical trials.MATERIALS AND METHODSThe Kidney Stone Engagement Core, a group of patients, caregivers, advocates, clinicians, and researchers, executed an iterative process of surveys and focus groups to elicit and refine research themes, which were then translated into research questions. A separate group of patients, caregivers, and clinicians prioritized these questions through parallel modified Delphi and crowd-sourced digital platforms. A research agenda was developed by the Kidney Stone Engagement Core based on the highest rated questions during a hybrid virtual/in-person capstone session.RESULTSA total of 70 individuals (57 patients and caregivers, 13 researchers and clinicians) participated in the elicitation, 20 individuals (15 patients and caregivers, 5 researchers and clinicians) participated in refinement, and an additional 80 individuals (81 patients and caregivers, 9 researchers and clinicians) participated in prioritization. Key novel themes emerged from elicitation and refinement: ureteral stents, genetic evaluation, shared surgical decision-making, key subgroups, cumulative disease burden, genetic evaluation, and psychosocial support. Stakeholders generated 6 proposed trials from these themes focused on surveillance, surgical intervention, and medical prevention.CONCLUSIONSPatients and caregivers valued comparative effectiveness kidney stone research that focused on individualized care, shared decision-making, and improvement of patient-reported experiences. This process provided actionable recommendations for future patient-centered clinical trials within kidney stone disease.","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"5 1","pages":"101097JU0000000000004242"},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142275257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-17DOI: 10.1097/ju.0000000000004253
Sigrid V Carlsson,Peter R Carroll,Freddie C Hamdy
{"title":"Reevaluating the Definition of \"Clinically Significant\" Prostate Cancer as Grade Groups 2-5: An Imperative for Improved Risk Stratification.","authors":"Sigrid V Carlsson,Peter R Carroll,Freddie C Hamdy","doi":"10.1097/ju.0000000000004253","DOIUrl":"https://doi.org/10.1097/ju.0000000000004253","url":null,"abstract":"","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"64 1","pages":"101097JU0000000000004253"},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142245458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PURPOSEA midline extraperitoneal approach for retroperitoneal lymph node dissection (EP-RPLND) has been associated with decreased morbidity compared to transperitoneal approach. We aimed to review our 11-year experience in patients with germ cell tumors (GCT) who underwent EP-RPLND at a single institution.METHODSAll patients with GCT who underwent EP-RPLND between 2010 to 2021 were reviewed. Surgical, peri-operative, and oncologic outcomes were reported. A logistic regression model was developed to evaluate variables predictive of early discharge. Oncologic outcomes included recurrence free survival (2-year RFS) and recurrence patterns, which were analyzed according to pathology.RESULTSOverall, 237 patients underwent EP-RPLND, of which 72% were in the post-chemotherapy (PC) setting. Median follow-up was 16.7(IQR 3.9-39.6) months. Median size of retroperitoneal disease was 2.8 (1.8-5.4)cm, of which 16 cases were > 10 cm. There were no cases of postoperative ileus or readmission due to small bowel obstruction. Median hospital stay was 2(IQR 1-3) days. From 2020 to 2021, 73% of patients were discharged on POD1 and 89% by POD2. Thirty-one complications occurred, including 4% grade III-IV. In the primary setting, 2-year RFS for seminoma and NSGCT were 0.93 (95% CI 0.84-1.00) and 0.85 (95% CI 0.72-1.00); respectively. In the PC setting, 2-year RFS for seminoma and NSGCT were 0.88 (95% CI 0.74-1.00) and 0.88 (95% CI 0.81-0.95); respectively. Overall, only 7 patients had in-field recurrence.CONCLUSIONSMidline EP-RPLND is safe, associated with rapid gastrointestinal recovery, short hospital stay, and low complication rates. It also demonstrates acceptable oncologic outcomes in the primary and post-chemotherapy settings, with low rates of in-field relapse.
目的腹膜后淋巴结清扫术（EP-RPLND）采用中线腹膜外方法，与经腹膜方法相比，发病率较低。我们旨在回顾一家医疗机构11年来对生殖细胞瘤（GCT）患者进行EP-RPLND的经验。方法回顾2010年至2021年期间接受EP-RPLND的所有GCT患者。报告了手术、围手术期和肿瘤学结果。建立了一个逻辑回归模型来评估早期出院的预测变量。肿瘤学结果包括无复发生存期（2 年 RFS）和复发模式，根据病理学进行分析。结果总计有 237 名患者接受了 EP-RPLND，其中 72% 为化疗后（PC）患者。中位随访时间为16.7（IQR 3.9-39.6）个月。腹膜后疾病的中位尺寸为2.8（1.8-5.4）厘米，其中16例大于10厘米。没有出现术后回肠梗阻或因小肠梗阻再次入院的病例。住院时间中位数为 2 天（IQR 1-3）。从2020年到2021年，73%的患者在POD1出院，89%在POD2出院。共发生 31 例并发症，其中 4% 为 III-IV 级。在初级治疗中，精原细胞瘤和NSGCT的2年RFS分别为0.93（95% CI 0.84-1.00）和0.85（95% CI 0.72-1.00）。在 PC 环境中，精原细胞瘤和 NSGCT 的 2 年 RFS 分别为 0.88（95% CI 0.74-1.00）和 0.88（95% CI 0.81-0.95）。结论中线 EP-RPLND 是安全的，胃肠道恢复快，住院时间短，并发症发生率低。此外，它在初治和化疗后的肿瘤治疗效果也是可以接受的，场内复发率较低。
{"title":"11-Year Experience With Midline Extraperitoneal Retroperitoneal Lymph Node Dissection for Germ Cell Tumors.","authors":"Muhannad Alsyouf,Alireza Ghoreifi,Arman Ashrafi,Seyedeh-Sanam Ladi-Seyedian,Hamed Ahmadi,Madeleine Burg,Antoin Douglawi,Qi Nie,Ming Li,Sumeet Bhanvadia,Anne Schuckman,Hooman Djaladat,Siamak Daneshmand","doi":"10.1097/ju.0000000000004246","DOIUrl":"https://doi.org/10.1097/ju.0000000000004246","url":null,"abstract":"PURPOSEA midline extraperitoneal approach for retroperitoneal lymph node dissection (EP-RPLND) has been associated with decreased morbidity compared to transperitoneal approach. We aimed to review our 11-year experience in patients with germ cell tumors (GCT) who underwent EP-RPLND at a single institution.METHODSAll patients with GCT who underwent EP-RPLND between 2010 to 2021 were reviewed. Surgical, peri-operative, and oncologic outcomes were reported. A logistic regression model was developed to evaluate variables predictive of early discharge. Oncologic outcomes included recurrence free survival (2-year RFS) and recurrence patterns, which were analyzed according to pathology.RESULTSOverall, 237 patients underwent EP-RPLND, of which 72% were in the post-chemotherapy (PC) setting. Median follow-up was 16.7(IQR 3.9-39.6) months. Median size of retroperitoneal disease was 2.8 (1.8-5.4)cm, of which 16 cases were > 10 cm. There were no cases of postoperative ileus or readmission due to small bowel obstruction. Median hospital stay was 2(IQR 1-3) days. From 2020 to 2021, 73% of patients were discharged on POD1 and 89% by POD2. Thirty-one complications occurred, including 4% grade III-IV. In the primary setting, 2-year RFS for seminoma and NSGCT were 0.93 (95% CI 0.84-1.00) and 0.85 (95% CI 0.72-1.00); respectively. In the PC setting, 2-year RFS for seminoma and NSGCT were 0.88 (95% CI 0.74-1.00) and 0.88 (95% CI 0.81-0.95); respectively. Overall, only 7 patients had in-field recurrence.CONCLUSIONSMidline EP-RPLND is safe, associated with rapid gastrointestinal recovery, short hospital stay, and low complication rates. It also demonstrates acceptable oncologic outcomes in the primary and post-chemotherapy settings, with low rates of in-field relapse.","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"46 1","pages":"101097JU0000000000004246"},"PeriodicalIF":0.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142233504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-10DOI: 10.1097/ju.0000000000004091
Ben H Chew,Jonathan D Harper,Roger L Sur,Thomas Chi,Shubha De,Anne R Buckley,Ryan F Paterson,Victor K F Wong,Connor M Forbes,M Kennedy Hall,Ross Kessler,Seth K Bechis,Jason R Woo,Ralph C Wang,David B Bayne,Derek Bochinski,Trevor D Schuler,Tim A Wollin,Rahim Samji,Mathew D Sorensen
PURPOSEThis study reports on a prospective, multicenter, single-arm, clinical trial utilizing the SonoMotion (San Mateo, California) Break Wave lithotripsy (BWL) device to fragment urinary stones.MATERIALS AND METHODSPatients with a urinary stone underwent a single treatment of 30 minutes and peak negative pressure of 4.5 to 8 MPa. Subjects were contacted and outcomes assessed at 7, 14, and 35 days after treatment, with clinical follow-up and CT imaging 70 ± 14 days postprocedure. The primary objectives were to assess the safety (hematomas, complications, etc) and effectiveness of BWL (any fragmentation, residual fragments ≤4 mm or ≤2 mm, and completely stone-free rate) as assessed via noncontrast CT-kidneys, ureters, and bladder.RESULTSForty-four patients with a ureteral (43%) or renal (57%) stone were treated across 5 centers. Stone fragmentation occurred in 88% of cases; 70% had fragments ≤ 4 and 51% ≤ 2 mm, while 49% were completely stone free on CT; no serious adverse events were reported. Eighty-six percent of patients received either no analgesic medication at all (50%) or minor analgesia (36%). After determining optimal therapy settings, 36 patients were treated and the effectiveness improved exhibiting fragmentation in 92% (33/36), residual fragments ≤ 4 mm in 75% and 58% with fragments ≤ 2 mm with 58% completely stone free. Effectiveness was less in subjects with lower pole stones with 81% fragmentation, 71% having fragments ≤ 4 mm, 29% with fragments ≤ 2 mm, and 29% completely stone free; of distal ureteral stone patients, 89% were completely stone free.CONCLUSIONSBWL offered safe and effective noninvasive stone therapy requiring little to no anesthesia and was carried out successfully in nonoperative environments.TRIAL REGISTRATIONClinicalTrials.gov identifier: NCT03811171.
{"title":"Break Wave Lithotripsy for Urolithiasis: Results of the First-in-Human International Multi-Institutional Clinical Trial.","authors":"Ben H Chew,Jonathan D Harper,Roger L Sur,Thomas Chi,Shubha De,Anne R Buckley,Ryan F Paterson,Victor K F Wong,Connor M Forbes,M Kennedy Hall,Ross Kessler,Seth K Bechis,Jason R Woo,Ralph C Wang,David B Bayne,Derek Bochinski,Trevor D Schuler,Tim A Wollin,Rahim Samji,Mathew D Sorensen","doi":"10.1097/ju.0000000000004091","DOIUrl":"https://doi.org/10.1097/ju.0000000000004091","url":null,"abstract":"PURPOSEThis study reports on a prospective, multicenter, single-arm, clinical trial utilizing the SonoMotion (San Mateo, California) Break Wave lithotripsy (BWL) device to fragment urinary stones.MATERIALS AND METHODSPatients with a urinary stone underwent a single treatment of 30 minutes and peak negative pressure of 4.5 to 8 MPa. Subjects were contacted and outcomes assessed at 7, 14, and 35 days after treatment, with clinical follow-up and CT imaging 70 ± 14 days postprocedure. The primary objectives were to assess the safety (hematomas, complications, etc) and effectiveness of BWL (any fragmentation, residual fragments ≤4 mm or ≤2 mm, and completely stone-free rate) as assessed via noncontrast CT-kidneys, ureters, and bladder.RESULTSForty-four patients with a ureteral (43%) or renal (57%) stone were treated across 5 centers. Stone fragmentation occurred in 88% of cases; 70% had fragments ≤ 4 and 51% ≤ 2 mm, while 49% were completely stone free on CT; no serious adverse events were reported. Eighty-six percent of patients received either no analgesic medication at all (50%) or minor analgesia (36%). After determining optimal therapy settings, 36 patients were treated and the effectiveness improved exhibiting fragmentation in 92% (33/36), residual fragments ≤ 4 mm in 75% and 58% with fragments ≤ 2 mm with 58% completely stone free. Effectiveness was less in subjects with lower pole stones with 81% fragmentation, 71% having fragments ≤ 4 mm, 29% with fragments ≤ 2 mm, and 29% completely stone free; of distal ureteral stone patients, 89% were completely stone free.CONCLUSIONSBWL offered safe and effective noninvasive stone therapy requiring little to no anesthesia and was carried out successfully in nonoperative environments.TRIAL REGISTRATIONClinicalTrials.gov identifier: NCT03811171.","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"41 1","pages":"580-589"},"PeriodicalIF":0.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142165936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter: Mayo Clinic Validation of the AUA Risk Groups for Localized Renal Cell Carcinoma.","authors":"Mattia Longoni,Giuseppe Rosiello,Alessandro Larcher,Francesco Montorsi,Umberto Capitanio","doi":"10.1097/ju.0000000000004123","DOIUrl":"https://doi.org/10.1097/ju.0000000000004123","url":null,"abstract":"","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"8 1","pages":"621"},"PeriodicalIF":0.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142165937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-17DOI: 10.1097/ju.0000000000004105
N Valeska Halstead, Ilina Rosoklija, David I Chu, Emilie K Johnson, Earl Y Cheng
To understand the general attitudes of pediatric urologists regarding the United States News and World Report rankings for Best Children's Hospitals in Urology.
了解儿科泌尿科医生对《美国新闻与世界报道》泌尿科最佳儿童医院排名的普遍态度。
{"title":"Pediatric Urologists' Views on the US News and World Report.","authors":"N Valeska Halstead, Ilina Rosoklija, David I Chu, Emilie K Johnson, Earl Y Cheng","doi":"10.1097/ju.0000000000004105","DOIUrl":"https://doi.org/10.1097/ju.0000000000004105","url":null,"abstract":"To understand the general attitudes of pediatric urologists regarding the United States News and World Report rankings for Best Children's Hospitals in Urology.","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"332 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141334305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-17DOI: 10.1097/ju.0000000000004010
Louise Emmett, Nathan Papa, Thomas A Hope, Wolfgang Fendler, Jeremie Calais, Irene Burger, Matthias Eiber, Francesco Barbato, Daniel Moon, William Counter, Nikeith John, Alan Xue, Anthony Franklin, James Thompson, Kris Rasiah, Mark Frydenberg, John Yaxley, James Buteau, Shikha Agrawal, Bao Ho, Andrew Nguyen, Victor Liu, Jonathan Lee, Henry Woo, Edward Hsiao, Thomas Sutherland, Elyse Perry, Phillip Stricker, Michael S Hofman, Veeru Kasivisvanathan, Matthew Roberts, Declan Murphy
The PI-RADS score is standard of care for clinically significant prostate cancer (csPCa) diagnosis. The PRIMARY-score (PSMA-PET/CT) also has high diagnostic accuracy for csPCa. This study aimed to develop an easily calculated combined (P) score for csPCa detection (ISUP ≥ 2) incorporating separately read PI-RADS and PRIMARY scores, with external validation.
{"title":"Beyond PI-RADS: Combining MRI PI-RADS and PSMA-PET/CT PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.","authors":"Louise Emmett, Nathan Papa, Thomas A Hope, Wolfgang Fendler, Jeremie Calais, Irene Burger, Matthias Eiber, Francesco Barbato, Daniel Moon, William Counter, Nikeith John, Alan Xue, Anthony Franklin, James Thompson, Kris Rasiah, Mark Frydenberg, John Yaxley, James Buteau, Shikha Agrawal, Bao Ho, Andrew Nguyen, Victor Liu, Jonathan Lee, Henry Woo, Edward Hsiao, Thomas Sutherland, Elyse Perry, Phillip Stricker, Michael S Hofman, Veeru Kasivisvanathan, Matthew Roberts, Declan Murphy","doi":"10.1097/ju.0000000000004010","DOIUrl":"https://doi.org/10.1097/ju.0000000000004010","url":null,"abstract":"The PI-RADS score is standard of care for clinically significant prostate cancer (csPCa) diagnosis. The PRIMARY-score (PSMA-PET/CT) also has high diagnostic accuracy for csPCa. This study aimed to develop an easily calculated combined (P) score for csPCa detection (ISUP ≥ 2) incorporating separately read PI-RADS and PRIMARY scores, with external validation.","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"126 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140953963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：